BioRestorative Therapies, Inc.

NasdaqCM:BRTX Stock Report

Market Cap: US$10.7m

BioRestorative Therapies Management

Management criteria checks 2/4

BioRestorative Therapies' CEO is Lance Alstodt, appointed in Nov 2020, has a tenure of 4.08 years. total yearly compensation is $1.25M, comprised of 38.2% salary and 61.8% bonuses, including company stock and options. directly owns 2.48% of the company’s shares, worth $266.40K. The average tenure of the management team and the board of directors is 4.1 years and 6.2 years respectively.

Key information

Lance Alstodt

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage38.2%
CEO tenure4.1yrs
CEO ownership2.5%
Management average tenure4.1yrs
Board average tenure6.2yrs

Recent management updates

Recent updates

BioRestorative begins enrollment in mid-stage study of stem cell therapy for lumbar disk disease

Jun 30

CEO Compensation Analysis

How has Lance Alstodt's remuneration changed compared to BioRestorative Therapies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$10m

Jun 30 2024n/an/a

-US$4m

Mar 31 2024n/an/a

-US$5m

Dec 31 2023US$1mUS$479k

-US$10m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$17m

Mar 31 2023n/an/a

-US$16m

Dec 31 2022US$452kUS$400k

-US$13m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$34m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$21mUS$275k

-US$44m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$64kUS$64k

-US$11m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$11m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$350kUS$350k

-US$15m

Sep 30 2019n/an/a

-US$17m

Jun 30 2019n/an/a

-US$15m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$750kUS$73k

-US$13m

Compensation vs Market: Lance's total compensation ($USD1.25M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Lance's compensation has increased whilst the company is unprofitable.

CEO

Lance Alstodt (53 yo)

4.1yrs

Tenure

US$1,254,167

Compensation

Mr. Lance Alstodt serves as President, Chief Executive Officer and Chairman of the Board at BioRestorative Therapies, Inc. since November 16, 2020 and also served as Executive Vice President & Chief Strate...

Leadership Team

NamePositionTenureCompensationOwnership
Lance Alstodt
Chairman of the Board4.1yrsUS$1.25m2.48%
$ 266.4k
Robert Kristal
Chief Financial Officer3.1yrsUS$618.12k0.12%
$ 12.4k
Francisco Silva
Chief Scientist4.1yrsUS$1.20m2.43%
$ 260.2k
Stephen Kilmer
Investor Relations Officerno datano datano data
Robert Paccasassi
Vice President of Quality Assurance & Regulatory Compliance9.3yrsUS$287.85kno data
Wayne Olan
Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board6.6yrsno datano data

4.1yrs

Average Tenure

54yo

Average Age

Experienced Management: BRTX's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Lance Alstodt
Chairman of the Board4.1yrsUS$1.25m2.48%
$ 266.4k
Francisco Silva
Chief Scientist4.1yrsUS$1.20m2.43%
$ 260.2k
Wayne Olan
Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board10.7yrsno datano data
Wayne Marasco
Chairman of Scientific Advisory Board12.3yrsno datano data
Joy Cavagnaro
Member of Scientific Advisory Board9.8yrsno datano data
Harvinder Sandhu
Member of Scientific Advisory Board6.2yrsno datano data
Patrick Williams
Independent Director3.1yrsUS$120.00k0%
$ 0
David Rosa
Independent Director3.1yrsUS$120.00k0%
$ 0
Nickolay Kukekov
Independent Director3.8yrsUS$120.00k0%
$ 0
Jason Lipetz
Member of Scientific Advisory Board6.4yrsno datano data
Christopher Plastaras
Member of Scientific Advisory Board6.2yrsno datano data

6.2yrs

Average Tenure

52yo

Average Age

Experienced Board: BRTX's board of directors are considered experienced (6.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 16:03
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioRestorative Therapies, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael OkunewitchMaxim Group
Elemer PirosRoth MKM
Jonathan AschoffRoth MKM